{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:57:47Z","timestamp":1782500267746,"version":"3.54.5"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"TEVA Nederland B.V."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Thioguanine is a well-tolerated and effective therapy for inflammatory bowel disease [IBD] patients. Prospective effectiveness data are needed to substantiate the role of thioguanine as a maintenance therapy for IBD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>IBD patients who previously failed azathioprine or mercaptopurine and initiated thioguanine were prospectively followed for 12 months starting when corticosteroid-free clinical remission was achieved (Harvey\u2013Bradshaw Index [HBI] \u2264 4 or Simple Clinical Colitis Activity Index [SCCAI] \u2264 2). The primary endpoint was corticosteroid-free clinical remission throughout 12 months. Loss of clinical remission was defined as SCCAI &amp;gt; 2 or HBI &amp;gt; 4, need of surgery, escalation of therapy, initiation of corticosteroids or study discontinuation. Additional endpoints were adverse events, drug survival, physician global assessment [PGA] and quality of life [QoL].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sustained corticosteroid-free clinical remission at 3, 6 or 12 months was observed in 75 [69%], 66 [61%] and 49 [45%] of 108 patients, respectively. Thioguanine was continued in 86 patients [80%] for at least 12 months. Loss of response [55%] included escalation to biologicals in 15%, corticosteroids in 10% and surgery in 3%. According to PGA scores, 82% of patients were still in remission after 12 months and QoL scores remained stable. Adverse events leading to discontinuation were reported in 11%, infections in 10%, myelo- and hepatotoxicity each in 6%, and portal hypertension in 1% of patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Sustained corticosteroid-free clinical remission over 12 months was achieved in 45% of IBD patients on monotherapy with thioguanine. A drug continuation rate of 80%, together with favourable PGA and QoL scores, underlines the tolerability and effectiveness of thioguanine for IBD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjad013","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T20:53:49Z","timestamp":1674507229000},"page":"933-942","source":"Crossref","is-referenced-by-count":9,"title":["Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Registry Study"],"prefix":"10.1093","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8827-955X","authenticated-orcid":false,"given":"Melek","family":"Simsek","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, AGEM Research Institute, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Schepers","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries , Haarlem , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigal","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries Ltd , Netanya , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"van Asseldonk","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Noordwest ziekenhuisgroep , Alkmaar , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"van Boeckel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology , Sint Antonius, Nieuwegein , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Boekema","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Maxima Medical Centre , Veldhoven , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Dijkstra","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Centre Groningen , Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herma","family":"Fidder","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Centre Utrecht , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Gisbertz","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Bernhoven Hospital , Uden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hoentjen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Radboud University Medical Centre , Nijmegen , The Netherlands"},{"name":"Division of Gastroenterology, Department of Medicine, University of Alberta , Edmonton , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindia","family":"Jharap","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Meander Medical Centre , Amersfoort , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kubben","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Maasstad Hospital , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"de Leest","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Rijnstate Hospital , Arnhem , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Meijssen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology , Isala Clinics, Zwolle , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Petrak","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries , Haarlem , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else","family":"van de Poel","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries , Haarlem , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Russel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Medical Spectrum Twente , Enschede , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A","family":"van Bodegraven","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Geriatrics, Internal and Intensive Care Medicine (CO-MIK), Zuyderland Medical Centre , Heerlen-Sittard-Geleen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J J","family":"Mulder","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, AGEM Research Institute, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanne","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, AGEM Research Institute, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"2023061613183371700_CIT0001","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/ibd\/izx100","article-title":"Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part I","volume":"24","author":"Knowles","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613183371700_CIT0002","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/ibd.21221","article-title":"Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts","volume":"16","author":"Jharap","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613183371700_CIT0003","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1080\/14712598.2016.1203897","article-title":"Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease","volume":"16","author":"Pouillon","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"2023061613183371700_CIT0004","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"2023061613183371700_CIT0005","doi-asserted-by":"crossref","first-page":"651415","DOI":"10.3389\/fphar.2021.651415","article-title":"Novel and emerging therapies for inflammatory bowel disease","volume":"12","author":"Al-Bawardy","year":"2021","journal-title":"Front Pharmacol"},{"key":"2023061613183371700_CIT0006","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.crohns.2010.07.005","article-title":"ECCO consensus: evidence-based use of 6-thioguanine therapy in Crohn\u2019s disease?","volume":"4","author":"de Boer","year":"2010","journal-title":"J Crohns Colitis"},{"key":"2023061613183371700_CIT0007","first-page":"111","article-title":"The continuous rediscovery and the benefit\u2013risk ratio of thioguanine, a comprehensive review","volume":"16","author":"Bayoumy","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2023061613183371700_CIT0008","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/apt.15280","article-title":"Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies","volume":"50","author":"Simsek","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2023061613183371700_CIT0009","doi-asserted-by":"crossref","first-page":"9012","DOI":"10.3748\/wjg.v22.i40.9012","article-title":"Efficacy of thioguanine treatment in inflammatory bowel disease: a systematic review","volume":"22","author":"Meijer","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2023061613183371700_CIT0010","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1097\/MIB.0000000000000206","article-title":"Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study","volume":"20","author":"Pavlidis","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613183371700_CIT0011","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0016-5085(03)00938-7","article-title":"6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients","volume":"125","author":"Dubinsky","year":"2003","journal-title":"Gastroenterology"},{"key":"2023061613183371700_CIT0012","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1111\/j.1572-0241.2007.01530.x","article-title":"6-Thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension","volume":"102","author":"Ferlitsch","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"2023061613183371700_CIT0013","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1097\/MIB.0000000000000869","article-title":"The prevalence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with thioguanine is not associated with clinically significant liver disease","volume":"22","author":"van Asseldonk","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2023061613183371700_CIT0014","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/00365521.2019.1629006","article-title":"Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients","volume":"54","author":"van Asseldonk","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"2023061613183371700_CIT0015","doi-asserted-by":"crossref","first-page":"e0212157","DOI":"10.1371\/journal.pone.0212157","article-title":"Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: a systematic review","volume":"14","author":"Toksvang","year":"2019","journal-title":"PLoS One"},{"key":"2023061613183371700_CIT0016","first-page":"1571","article-title":"The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn\u2019s Relapse Prevention Trial","volume":"91","author":"Irvine","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"2023061613183371700_CIT0017"},{"key":"2023061613183371700_CIT0018","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.2042-7158.1983.tb04255.x","article-title":"Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells","volume":"35","author":"Lennard","year":"1983","journal-title":"J Pharm Pharmacol"},{"key":"2023061613183371700_CIT0019","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/gutjnl-2019-320185","article-title":"Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn\u2019s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource","volume":"70","author":"Stournaras","year":"2021","journal-title":"Gut"},{"key":"2023061613183371700_CIT0020","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/apt.17128","article-title":"Classic drugs in the time of new drugs: real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease","volume":"56","author":"Rezazadeh Ardabili","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2023061613183371700_CIT0021","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12876-020-01441-6","article-title":"Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom","volume":"20","author":"Bayoumy","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"2023061613183371700_CIT0022","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/ecco-jcc\/jjac044","article-title":"Safety and drug survival of methotrexate versus tioguanine after failure of conventional thiopurines in patients with Crohn\u2019s disease.","volume":"16","author":"Savelkoul","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2023061613183371700_CIT0023","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/hep.1840110512","article-title":"Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2500 autopsies and a new classification of benign hepatocellular nodules","volume":"11","author":"Wanless","year":"1990","journal-title":"Hepatology"},{"key":"2023061613183371700_CIT0024","doi-asserted-by":"crossref","first-page":"637","DOI":"10.15403\/jgld-2765","article-title":"Thioguanine therapy in inflammatory bowel diseases. a practical guide","volume":"29","author":"Crouwel","year":"2020","journal-title":"J Gastrointestin Liver Dis"},{"key":"2023061613183371700_CIT0025","article-title":"Exposure to thioguanine during 117 pregnancies in women with inflammatory bowel disease","author":"Crouwel","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2023061613183371700_CIT0026","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/FTD.0000000000000455","article-title":"Analytical pitfalls of therapeutic drug monitoring of thiopurines in patients with inflammatory bowel disease","volume":"39","author":"Simsek","year":"2017","journal-title":"Ther Drug Monit"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjad013\/49393408\/jjad013.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/17\/6\/933\/50627579\/jjad013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/17\/6\/933\/50627579\/jjad013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T13:19:33Z","timestamp":1686921573000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/17\/6\/933\/7005319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,1,25]]},"published-print":{"date-parts":[[2023,6,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad013","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,1,25]]}}}